{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:48:55Z","timestamp":1782499735534,"version":"3.54.5"},"reference-count":138,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006806","name":"Hollings Cancer Center, Medical University of South Carolina","doi-asserted-by":"publisher","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}],"id":[{"id":"10.13039\/100006806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA282730"],"award-info":[{"award-number":["R01CA282730"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA168814"],"award-info":[{"award-number":["R01CA168814"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA232491"],"award-info":[{"award-number":["U01CA232491"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020812","name":"Robert K Steel Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xcrm.2026.102772","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:58:18Z","timestamp":1777301898000},"page":"102772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-2775","authenticated-orcid":false,"given":"Sophie","family":"Paczesny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali P.","family":"Barwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilkumar","family":"Gopalakrishnapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102772_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib3","unstructured":"SEER (2025). Cancer Stat Facts: Leukemia\u2014Acute Myeloid Leukemia (AML) https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"10.1016\/j.xcrm.2026.102772_bib4","first-page":"849","article-title":"Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database","volume":"26","author":"Pandya","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.xcrm.2026.102772_bib5","series-title":"Abeloff\u2019s Clinical Oncology","article-title":"Chapter 95: Acute leukemias in adults","author":"Appelbaum","year":"2020"},{"key":"10.1016\/j.xcrm.2026.102772_bib6","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102772_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.2024027264","article-title":"Introduction to a How I Treat series on acute myeloid leukemia","volume":"145","author":"Luger","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.xcrm.2026.102772_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib11","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/bloodadvances.2019000357","article-title":"Opportunities for immunotherapy in childhood acute myeloid leukemia","volume":"3","author":"Lamble","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102772_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14712598.2018.1384463","article-title":"Advances in immunotherapy for pediatric acute myeloid leukemia","volume":"18","author":"Bonifant","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102772_bib14","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib15","first-page":"68","article-title":"Gemtuzumab Ozogamicin: Back Again","volume":"10","author":"Selby","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14712598.2021.1825678","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults","volume":"21","author":"Goldenson","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/leu.2008.246","article-title":"Targeting the leukemic stem cell: the Holy Grail of leukemia therapy","volume":"23","author":"Misaghian","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102772_bib20","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1007\/s00277-024-06117-9","article-title":"Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies","volume":"103","author":"Zha","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.xcrm.2026.102772_bib21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2024-208684","article-title":"Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2023-173302","article-title":"Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML)","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib23","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2023-173353","article-title":"MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed\/Refractory AML or MDS\/AML: Preliminary Results of a Phase 1\/2a Study","volume":"142","author":"Pabst","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102772_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","article-title":"MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis","volume":"19","author":"van Loo","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib27","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102772_bib28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2024-206538","article-title":"IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results","volume":"144","author":"Mannis","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004222","article-title":"Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia","volume":"10","author":"Trad","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102772_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-024-01586-x","article-title":"IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/leu.2016.35","article-title":"High-affinity FRbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity","volume":"30","author":"Lynn","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102772_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/hem.V22.2.202529","article-title":"Targeting the Rare: A New Therapy for Pediatric Acute Myeloid Leukemia with CBFA2T3-GLIS2 Fusions","volume":"22","author":"Furlan","year":"2025","journal-title":"Hematologist"},{"key":"10.1016\/j.xcrm.2026.102772_bib33","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3324\/haematol.2023.283757","article-title":"CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group","volume":"109","author":"Menssen","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102772_bib34","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/bloodadvances.2024013212","article-title":"Targeting CD38 with isatuximab and a novel CD38\/CD3\u00d7CD28 trispecific T-cell engager in older patients with acute myeloid leukemia","volume":"8","author":"Mart\u00edn-S\u00e1nchez","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102772_bib35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s43018-025-00934-1","article-title":"CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant","volume":"6","author":"Ikeda","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102772_bib36","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1158\/1078-0432.CCR-21-1546","article-title":"Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia","volume":"27","author":"Le","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235964","article-title":"Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies","volume":"13","author":"Gopalakrishnapillai","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102772_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102772_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.add7705","article-title":"IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways","volume":"16","author":"Naef","year":"2023","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2026.102772_bib40","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1038\/s41467-025-61647-8","article-title":"ST2\/IL-33 Axis Blockade Inhibits Regulatory T Cell Cytotoxicity Towards CD8 T Cells In The Leukemic Niche","volume":"16","author":"Jiang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102772_bib41","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.1038\/s41467-025-61567-7","article-title":"Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33\/IL1RL1 pathway","volume":"16","author":"Fu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102772_bib42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102772_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025018830","article-title":"DLK1 Is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia","author":"Verboon","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102772_bib44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2023-188439","article-title":"CLEC2A Is a Novel AML-Restricted Immunotherapeutic Target Enriched in KMT2A-Rearranged Acute Myeloid Leukemia","volume":"142","author":"Kirkey","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib45","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jtct.2025.01.086","article-title":"CLEC2A Is a Novel Immunotherapeutic Target with Robust Anti-Leukemia Efficacy in Preclinical Models of Acute Myeloid Leukemia","volume":"31","author":"Kirkey","year":"2025","journal-title":"Transplantation and Cellular Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib46","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1084\/jem.20190598","article-title":"CD97 is a critical regulator of acute myeloid leukemia stem cell function","volume":"216","author":"Martin","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102772_bib47","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102772_bib48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2025-385","article-title":"Unbiased in-depth surfaceome profiling of Acute Myeloid Leukemia reveals novel immunotherapy targets beyond canonical membrane proteins","volume":"146","author":"Barpanda","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib49","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib50","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.xcrm.2026.102772_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33 \u00d7 CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.xcrm.2026.102772_bib52","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Mu\u00f1oz","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102772_bib53","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1182\/blood-2022-167468","article-title":"Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir\u2122 Molecule, in Relapsed\/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"140","author":"Watts","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib54","article-title":"Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia","volume":"11","author":"Barwe","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.xcrm.2026.102772_bib55","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1158\/1078-0432.CCR-17-2265","article-title":"Integrated Pharmacokinetic\/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity","volume":"24","author":"Campagne","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib57","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1182\/blood-2022-159524","article-title":"A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart\u00ae Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies","volume":"140","author":"Winer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.xcrm.2026.102772_bib59","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2024-194356","article-title":"Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE\u00ae) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed\/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study","volume":"144","author":"Montesinos","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib60","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1182\/bloodadvances.2024015449","article-title":"Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia","volume":"9","author":"Liegel","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102772_bib61","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib62","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2024-194162","article-title":"CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia","volume":"144","author":"Geyer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib63","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2024-194391","article-title":"Developing an Optimal Fully-Human CD371-Targeting IL-18 Secreting CAR T Cell for the Treatment of Acute Myeloid Leukemia","volume":"144","author":"Shahid","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib64","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102772_bib65","doi-asserted-by":"crossref","first-page":"1561823","DOI":"10.3389\/fimmu.2025.1561823","article-title":"CLEC12A-directed immunocytokine with target cell\u2013restricted IL-15 activity for treatment of acute myeloid leukemia","volume":"16","author":"Klimovich","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102772_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543776.2024.2446224","article-title":"Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review","volume":"35","author":"Gorecki","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.xcrm.2026.102772_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117788","article-title":"Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges","volume":"182","author":"Rataj","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.xcrm.2026.102772_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003882","article-title":"A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL","volume":"10","author":"Mehta","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102772_bib69","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00428-024-03741-8","article-title":"Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents","volume":"485","author":"Marques-Piubelli","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.xcrm.2026.102772_bib71","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102772_bib72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib73","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pbc.23352","article-title":"Aggressive peripheral CD70-positive t-cell lymphoma associated with severe chronic active EBV infection","volume":"59","author":"Shaffer","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.xcrm.2026.102772_bib74","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(23)00207-7","article-title":"Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study","volume":"10","author":"Pabst","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.xcrm.2026.102772_bib75","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102772_bib76","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2024-199634","article-title":"PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, In Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study","volume":"144","author":"Nicole","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib77","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib78","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib79","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2023-173582","article-title":"A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia","volume":"142","author":"Sauter","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib80","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102772_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70055","article-title":"A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"8","author":"Volta","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.xcrm.2026.102772_bib82","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2023-185533","volume":"142","author":"Gandhi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 Inhibitors in Oncology Clinical Trials: A Review","volume":"7","author":"Feustel","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib84","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/1538-7445.AM2024-5255","article-title":"Abstract 5255: A B7-H3-CAR-modified V\u03b41 T cells showed potentanti-solid tumor potential","volume":"84","author":"Jiang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib85","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102772_bib86","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib87","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","article-title":"Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS","volume":"120","author":"Barreyro","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib88","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.V100.2.594","article-title":"Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid","volume":"100","author":"Pan","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib89","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib90","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood-2024-210048","article-title":"S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies","volume":"144","author":"Maragno","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib91","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2024-202691","article-title":"CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia","volume":"144","author":"Moujalled","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70245","article-title":"Isatuximab in combination with chemotherapy for pediatric patients with relapsed\/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study","volume":"9","author":"Baruchel","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.xcrm.2026.102772_bib93","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2023-187721","article-title":"A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed\/Refractory Acute Myeloid Leukemia","volume":"142","author":"Guru Murthy","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib94","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.ymthe.2023.05.009","article-title":"Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation","volume":"31","author":"Cieniewicz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib95","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood-2009-03-212746","article-title":"An upstream insulator regulates DLK1 imprinting in AML","volume":"115","author":"Khoury","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib96","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/sj.leu.2403832","article-title":"Dlk1 in normal and abnormal hematopoiesis","volume":"19","author":"Sakajiri","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102772_bib97","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13148-019-0643-z","article-title":"Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival","volume":"11","author":"Sellers","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.xcrm.2026.102772_bib98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antib4020071","article-title":"A Monoclonal Antibody to Human DLK1 Reveals Differential Expression in Cancer and Absence in Healthy Tissues","volume":"4","author":"Bujak","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.xcrm.2026.102772_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113374","article-title":"The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability","volume":"42","author":"Ravn-Boess","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102772_bib100","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V122.21.3972.3972","article-title":"Targeting CD96 For Antibody Based Elimination Of Leukemic Stem Cells In AML: A New Strategy In Stem Cell Transplantation","volume":"122","author":"Staudinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2015.11.590","article-title":"CD96 Antibody TH-111 Eradicates AML-LSC from Autografts and the Fc- Engineered Variant MSH-TH111e May be Used In Vivo","volume":"22","author":"Gramatzki","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.xcrm.2026.102772_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082171","article-title":"Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia","volume":"12","author":"Valhondo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102772_bib103","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","article-title":"Immunotherapy in pediatric acute lymphoblastic leukemia","volume":"38","author":"Inaba","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.xcrm.2026.102772_bib104","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102772_bib105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-018-0299-9","article-title":"Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies","volume":"32","author":"Husain","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.xcrm.2026.102772_bib106","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00262-021-03008-0","article-title":"CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL","volume":"70","author":"Reusing","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102772_bib107","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib108","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2026.102772_bib109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136398","article-title":"GTB-3550 TriKE\u2122 for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory\/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts","volume":"136","author":"Warlick","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-025-00624-9","article-title":"Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors","volume":"14","author":"Luo","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib111","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2551205","article-title":"A bispecific antibody-drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia","volume":"17","author":"Griffiths","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2026.102772_bib112","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102772_bib113","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41557-023-01280-4","article-title":"Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer","volume":"15","author":"Szijj","year":"2023","journal-title":"Nat. Chem."},{"key":"10.1016\/j.xcrm.2026.102772_bib114","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","article-title":"Bifunctional PD-1 \u00d7 \u03b1CD3 \u00d7 \u03b1CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia","volume":"132","author":"Herrmann","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102772_bib116","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/2326-6066.CIR-14-0230-T","article-title":"Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody","volume":"3","author":"Xu","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib117","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1315","article-title":"Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies","volume":"12","author":"Santich","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102772_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102772_bib119","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1320625","article-title":"Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2","volume":"6","author":"Hoseini","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2026.102772_bib120","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.2023021680","article-title":"CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia","volume":"144","author":"Mazziotta","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib121","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102772_bib122","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4062\/biomolther.2022.015","article-title":"Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy","volume":"30","author":"Cho","year":"2022","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.xcrm.2026.102772_bib123","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xcrm.2026.102772_bib124","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1038\/s41467-024-53839-5","article-title":"A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice","volume":"15","author":"Mebrahtu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102772_bib125","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad013","article-title":"Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment","volume":"3","author":"Zhu","year":"2023","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.xcrm.2026.102772_bib126","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00262-023-03439-x","article-title":"CD33 BiTE(\u00ae) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells","volume":"72","author":"Marcinek","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102772_bib127","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1158\/1538-7445.AM2025-640","article-title":"Abstract 640: Augmenting T-cell bispecific antibody therapy in AML through co-stimulatory agonists","volume":"85","author":"Neumann","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib128","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood-2025-866","article-title":"Menin-inhibition boosts CAR-T cell therapy against NPM1 mutated and KMT2A-rearranged acute myeloid leukemia","volume":"146","author":"Rausch","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib129","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib130","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2024-208389","article-title":"Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager","volume":"144","author":"Varkey","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib131","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102772_bib132","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102772_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102772_bib134","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102772_bib135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/cei\/uxad120","article-title":"Tuning the potency and selectivity of ImmTAC molecules by affinity modulation","volume":"215","author":"Robertson","year":"2024","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.xcrm.2026.102772_bib136","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102772_bib137","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.102772_bib138","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102772_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101224","article-title":"CD33 directed bispecific antibodies in acute myeloid leukemia","volume":"33","author":"Clark","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:04:22Z","timestamp":1782497062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":138,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666379126001898"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102772","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102772"}}